Research Analysts Offer Predictions for ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska anticipates that the biopharmaceutical company will post earnings per share of $0.05 for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.

A number of other research firms have also commented on ESPR. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 price target on the stock. JMP Securities reissued a “market outperform” rating and set a $7.00 price objective on shares of Esperion Therapeutics in a report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Esperion Therapeutics currently has an average rating of “Hold” and an average price target of $7.25.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $2.08 on Wednesday. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The company has a market capitalization of $409.84 million, a price-to-earnings ratio of -3.25 and a beta of 1.03. The company’s 50-day moving average is $2.46 and its 200 day moving average is $2.18.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $51.63 million for the quarter, compared to analyst estimates of $55.44 million. During the same quarter in the prior year, the firm earned ($0.37) earnings per share.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Xponance Inc. bought a new position in Esperion Therapeutics in the 2nd quarter worth $28,000. Traphagen Investment Advisors LLC bought a new position in shares of Esperion Therapeutics in the third quarter worth about $27,000. American Century Companies Inc. purchased a new position in shares of Esperion Therapeutics during the 2nd quarter valued at about $50,000. SJS Investment Consulting Inc. bought a new position in shares of Esperion Therapeutics during the 4th quarter valued at approximately $55,000. Finally, Versor Investments LP purchased a new stake in Esperion Therapeutics in the 3rd quarter worth approximately $44,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.